ZAP-X Gyroscopic Radiosurgery Platform Debuts at Kaohsiung Show Chwan Memorial Hospital

ZAP-X Gyroscopic Radiosurgery Platform Debuts at Kaohsiung Show Chwan Memorial Hospital ZAP Surgical Systems, Inc., a leader in non-invasive robotic brain surgery, has announced the installation of Taiwan’s first vault-free ZAP-X® Gyroscopic Radiosurgery® platform at Kaohsiung Show Chwan Memorial Hospital…

Read MoreZAP-X Gyroscopic Radiosurgery Platform Debuts at Kaohsiung Show Chwan Memorial Hospital

RenovoRx Reports Initial Revenues from RenovoCath® and Phase III TIGeR-PaC Trial Update

RenovoRx Reports Initial Revenues from RenovoCath® and Phase III TIGeR-PaC Trial Update RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company focused on developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel FDA-cleared drug delivery device, has announced its financial…

Read MoreRenovoRx Reports Initial Revenues from RenovoCath® and Phase III TIGeR-PaC Trial Update

Siemens Healthineers’ Antithrombin Blood Test FDA Cleared as Companion Diagnostic for Sanofi’s Qfitlia Hemophilia Therapy

Siemens Healthineers’ Antithrombin Blood Test FDA Cleared as Companion Diagnostic for Sanofi’s Qfitlia Hemophilia Therapy Siemens Healthineers announced that its Innovance Antithrombin assay has received FDA clearance for a new indication, allowing it to be used as a companion diagnostic…

Read MoreSiemens Healthineers’ Antithrombin Blood Test FDA Cleared as Companion Diagnostic for Sanofi’s Qfitlia Hemophilia Therapy

Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint

Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint Corcept Therapeutics Incorporated (NASDAQ: CORT), a company focused on developing treatments for serious endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol, announced that its pivotal…

Read MoreCorcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint

ENDRA Life Sciences Announces Strategy for Early Detection and Management of Metabolic Diseases with GLP-1 Therapies

ENDRA Life Sciences Announces Strategy for Early Detection and Management of Metabolic Diseases with GLP-1 Therapies ENDRA Life Sciences Inc. (NASDAQ: NDRA), a leader in Thermo-Acoustic Enhanced UltraSound (TAEUS®) technology, recently announced a new strategic direction to develop and deploy…

Read MoreENDRA Life Sciences Announces Strategy for Early Detection and Management of Metabolic Diseases with GLP-1 Therapies

ABEC Launches Breakthrough Single-Use Bioreactor Technology for Cell Therapy

ABEC Launches Breakthrough Single-Use Bioreactor Technology for Cell Therapy ABEC, a global leader in engineered solutions and services for biotech manufacturing, has unveiled its Advanced Therapy Bioreactor (ATB™), a groundbreaking platform designed to revolutionize cell expansion for Advanced Therapy Medicinal…

Read MoreABEC Launches Breakthrough Single-Use Bioreactor Technology for Cell Therapy

Exact Sciences Launches Cologuard Plus™ Test for Colorectal Cancer Screening

Exact Sciences Launches Cologuard Plus™ Test for Colorectal Cancer Screening Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer screening and diagnostic tests, has announced the launch of Cologuard Plus™, a groundbreaking noninvasive colorectal cancer (CRC) screening test. The Cologuard…

Read MoreExact Sciences Launches Cologuard Plus™ Test for Colorectal Cancer Screening

Enigma Biomedical Partners to Use 4R PET Imaging Biomarkers in CTE Research

Enigma Biomedical Partners to Use 4R PET Imaging Biomarkers in CTE Research Enigma Biomedical USA, Inc. (EB USA) has announced an exciting new collaboration with the Boston University Chronic Traumatic Encephalopathy (CTE) Center and the Concussion Legacy Foundation. This partnership…

Read MoreEnigma Biomedical Partners to Use 4R PET Imaging Biomarkers in CTE Research